$BOTH
BIOETHICS LTD

2023 Q4 Form 10-Q Financial Statement

#000109690623002192 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.60K $10.00K $10.50K
YoY Change 52.81% -4.76% -29.39%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $13.60K $10.00K $10.50K
YoY Change 52.81% -4.71% -29.4%
Operating Profit -$10.00K -$10.50K
YoY Change -4.71% -29.42%
Interest Expense -$10.80K $12.30K $11.71K
YoY Change -8.47% 5.04% -208.09%
% of Operating Profit
Other Income/Expense, Net -$12.30K -$11.71K
YoY Change 5.04% 8.06%
Pretax Income -$24.40K -$22.30K -$22.20K
YoY Change 17.87% 0.43% -13.64%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$24.40K -$22.30K -$22.20K
YoY Change 17.87% 0.43% -13.64%
Net Earnings / Revenue
Basic Earnings Per Share -$0.02 -$0.02
Diluted Earnings Per Share -$0.02 -$0.02 -$19.56K
COMMON SHARES
Basic Shares Outstanding 1.135M shares 1.135M shares 1.135M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $140.00 $480.00 $560.00
YoY Change -53.33% -14.29% 1.82%
Cash & Equivalents $138.00 $483.00 $559.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $138.00 $483.00 $559.00
YoY Change -53.22% -13.6% 1.64%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $138.00 $483.00 $559.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $138.00 $483.00 $559.00
YoY Change -53.22% -13.6% -1.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $122.4K $116.5K $96.18K
YoY Change 22.08% 21.12% 17.4%
Accrued Expenses $98.36K $94.74K $73.94K
YoY Change 24.23% 28.13% -20.54%
Deferred Revenue
YoY Change
Short-Term Debt $442.7K $436.9K $417.5K
YoY Change 5.27% 4.63% 7.59%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $776.4K $752.3K $659.0K
YoY Change 14.28% 14.17% 17.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $776.4K $752.3K $659.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $776.4K $752.3K $659.0K
YoY Change 14.28% 14.17% 17.03%
SHAREHOLDERS EQUITY
Retained Earnings -$1.278M -$1.253M -$1.160M
YoY Change 8.23% 8.06%
Common Stock $1.135K $1.135K $1.135K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$776.3K -$751.9K -$658.4K
YoY Change
Total Liabilities & Shareholders Equity $138.00 $483.00 $559.00
YoY Change -53.22% -13.6% -1.93%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$24.40K -$22.30K -$22.20K
YoY Change 17.87% 0.43% -13.64%
Depreciation, Depletion And Amortization $0.00
YoY Change -100.0%
Cash From Operating Activities -$6.200K -$13.06K -$3.690K
YoY Change 87.31% 253.93% -69.28%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.850K 13.30K 3.950K
YoY Change 91.8% 236.71% -67.36%
NET CHANGE
Cash From Operating Activities -6.200K -13.06K -3.690K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 5.850K 13.30K 3.950K
Net Change In Cash -350.0 240.0 260.0
YoY Change 34.62% -7.69% 188.89%
FREE CASH FLOW
Cash From Operating Activities -$6.200K -$13.06K -$3.690K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
33-55254-41
dei Entity Registrant Name
EntityRegistrantName
BIOETHICS, LTD.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0485312
dei Entity Address Address Line1
EntityAddressAddressLine1
1661 Lakeview Circle
dei Entity Address City Or Town
EntityAddressCityOrTown
Ogden
dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84403
dei City Area Code
CityAreaCode
801
dei Local Phone Number
LocalPhoneNumber
399-3632
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
true
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1135194 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
483 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
295 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
483 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
295 usd
CY2023Q3 us-gaap Assets
Assets
483 usd
CY2022Q4 us-gaap Assets
Assets
295 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
116496 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
100265 usd
CY2023Q3 fil Accounts Payable Related Party
AccountsPayableRelatedParty
13000 usd
CY2022Q4 fil Accounts Payable Related Party
AccountsPayableRelatedParty
8500 usd
CY2023Q3 fil Accrued Interest Related Parties
AccruedInterestRelatedParties
91229 usd
CY2022Q4 fil Accrued Interest Related Parties
AccruedInterestRelatedParties
70883 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
94736 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
79179 usd
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
35000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
35000 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
160000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
160000 usd
CY2023Q3 fil Notes Payable Related Parties
NotesPayableRelatedParties
241884 usd
CY2022Q4 fil Notes Payable Related Parties
NotesPayableRelatedParties
225584 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
752345 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
679411 usd
CY2023Q3 us-gaap Liabilities
Liabilities
752345 usd
CY2022Q4 us-gaap Liabilities
Liabilities
679411 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1135194 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1135194 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1135194 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1135194 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1135 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1135 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
500479 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
500479 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1253476 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1180730 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-751862 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-679116 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
483 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
295 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
CY2022Q3 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10004 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10498 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36843 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38407 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
10004 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
10498 usd
us-gaap Operating Expenses
OperatingExpenses
36843 usd
us-gaap Operating Expenses
OperatingExpenses
38407 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10004 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10498 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-36843 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-38407 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
12296 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
11706 usd
us-gaap Interest Expense
InterestExpense
35903 usd
us-gaap Interest Expense
InterestExpense
34096 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12296 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11706 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-35903 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-34096 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22300 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22204 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72746 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72503 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-22300 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-22204 usd
us-gaap Profit Loss
ProfitLoss
-72746 usd
us-gaap Profit Loss
ProfitLoss
-72503 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2023Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1135194 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1135194 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1135194 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1135194 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-679116 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-23636 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-702752 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-26810 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-729562 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-22300 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-751862 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-585913 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-21679 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-607592 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-28620 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-636212 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-22204 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-658416 usd
us-gaap Profit Loss
ProfitLoss
-72746 usd
us-gaap Profit Loss
ProfitLoss
-72503 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
16231 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
16582 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
4500 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-500 usd
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
20346 usd
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
18775 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
15557 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
15321 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16112 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22325 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
16300 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
12150 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16300 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22150 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
188 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-175 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
295 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
734 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
483 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
559 usd
us-gaap Interest Paid
InterestPaid
0 usd
us-gaap Interest Paid
InterestPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1135194 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1135194 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1135194 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1135194 shares
us-gaap Profit Loss
ProfitLoss
1253476 usd
us-gaap Profit Loss
ProfitLoss
-72746 usd
us-gaap Profit Loss
ProfitLoss
-72503 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
fil Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.06
fil Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.06
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
15281 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
14109 shares
us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
1150475 shares
us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
1149303 shares

Files In Submission

Name View Source Status
0001096906-23-002192-index-headers.html Edgar Link pending
0001096906-23-002192-index.html Edgar Link pending
0001096906-23-002192.txt Edgar Link pending
0001096906-23-002192-xbrl.zip Edgar Link pending
both-20230930.htm Edgar Link pending
both-20230930.xsd Edgar Link pending
both_ex31z1.htm Edgar Link pending
both_ex32z1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
both-20230930_cal.xml Edgar Link unprocessable
both-20230930_def.xml Edgar Link unprocessable
both-20230930_lab.xml Edgar Link unprocessable
both-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
both-20230930_htm.xml Edgar Link completed